Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

M Pazianas; B Abrahamsen; Y Wang; R G G Russell

doi:10.1007/s00198-012-1952-7

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

M Pazianas, B Abrahamsen, Y Wang, R G G Russell

27 Citations (Scopus)

Abstract

In a cohort study of users of bisphosphonates, we evaluated the incidence of fragility fractures at all sites on the femur following for up to 8 years of therapy with alendronate or risedronate. We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates.

Original language	English
Journal	Osteoporosis International
Volume	23
Issue number	12
Pages (from-to)	2873-84
Number of pages	12
ISSN	0937-941X
DOIs	https://doi.org/10.1007/s00198-012-1952-7
Publication status	Published - 2012

Access to Document

10.1007/s00198-012-1952-7

Cite this

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases. / Pazianas, M; Abrahamsen, B; Wang, Y et al.
In: Osteoporosis International, Vol. 23, No. 12, 2012, p. 2873-84.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{026aac3d665f49e6adea0db3926cb6b4,

title = "Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases",

abstract = "In a cohort study of users of bisphosphonates, we evaluated the incidence of fragility fractures at all sites on the femur following for up to 8 years of therapy with alendronate or risedronate. We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates.",

author = "M Pazianas and B Abrahamsen and Y Wang and Russell, \{R G G\}",

year = "2012",

doi = "10.1007/s00198-012-1952-7",

language = "English",

volume = "23",

pages = "2873--84",

journal = "Osteoporosis International",

issn = "0937-941X",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

TY - JOUR

T1 - Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy

T2 - a register-based cohort study using the US MarketScan claims databases

AU - Pazianas, M

AU - Abrahamsen, B

AU - Wang, Y

AU - Russell, R G G

PY - 2012

Y1 - 2012

N2 - In a cohort study of users of bisphosphonates, we evaluated the incidence of fragility fractures at all sites on the femur following for up to 8 years of therapy with alendronate or risedronate. We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates.

AB - In a cohort study of users of bisphosphonates, we evaluated the incidence of fragility fractures at all sites on the femur following for up to 8 years of therapy with alendronate or risedronate. We did not find evidence for a reversal of fracture protection with long-term use of bisphosphonates.

UR - https://www.scopus.com/pages/publications/84872072934

U2 - 10.1007/s00198-012-1952-7

DO - 10.1007/s00198-012-1952-7

M3 - Journal article

C2 - 22431012

SN - 0937-941X

VL - 23

SP - 2873

EP - 2884

JO - Osteoporosis International

JF - Osteoporosis International

IS - 12

ER -

Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases

Abstract

Access to Document

Other files and links

Fingerprint

Cite this